LB Pharmaceuticals Inc
LBRX•NASDAQ•Healthcare•Biotechnology

About LB Pharmaceuticals

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOHeather Turner
Founded2015
IPO DateSeptember 11, 2025
Employees16
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitelbpharma.us
Phone212 605 0300
Address
One Pennsylvania Plaza, Suite 1025 New York, New York 10119 United States

Corporate Identifiers

CIK0001691082
CUSIP50180M108
ISINUS50180M1080
SIC2834

Leadership Team & Key Executives

Zachary Prensky
Co-founder, Advisor to the Chief Executive Officer and Director
Heather D. Turner J.D.
Chief Executive Officer and Director
Dr. Anna Eramo M.D.
Chief Medical Officer
Marc L. Panoff CPA
Senior Vice President of Finance
Gad Soffer
Chief Business Officer
Dr. Richard Silva Ph.D.
Senior Vice President of Technical Operations
Dr. James Rawls Pharm.D.
Senior Vice President of Regulatory Affairs